Scientists have discovered an antibody that prevents the coronavirus from infecting human cells in “groundbreaking research” that could lead to the development of new treatments.
Building on research on SARS coronavirus, scientists from the University of Utrect in the Netherlands, as well as the Erasmus Medical Center and Harbor BioMed (HBM), have identified a potential method of neutralization COVID-19[female[feminine.
They discovered that an antibody that prevents the SARS virus from infecting human cells could also prevent the new coronavirus from infecting human cells, according to a peer-reviewed study published in the journal Nature Communications on Monday.
By testing their collection of antibodies on cultured human cells, the researchers discovered one that binds to a specific part that is present both in SARS and in the virus that causes COVID-19.
The discovery could offer a first step towards the development of a fully human antibody to treat or prevent the disease, which has infected more than 3.5 million people worldwide and has caused more than 247,000 deaths.
Neutralizing antibody “has the potential to change the course of infection in the infected host, support the elimination of the virus or protect an uninfected individual who is exposed to the virus,” said Dr. Berend-Jan Bosch, lead co-author of the study.
Dr. Frank Grosveld, the other lead co-author of the study, said the discovery provided “a solid basis for further research to characterize this antibody and begin development as a potential treatment for COVID-19” .
“The antibody used in this work is” fully human “, allowing for faster development and reducing the potential for side effects related to immunity,” he added.
The fully human antibody is different from conventional therapeutic antibodies, which are often first developed in other species before being “humanized” so that they can be transmitted to humans.
It was developed using H2L2 transgenic mouse technology from Harbor BioMed – in fact a mouse that was genetically engineered to contain human genes, allowing researchers to develop “human” antibodies without testing them on living people.
“This is groundbreaking research,” said Dr. Jingsong Wang, managing director of HBM.